PMCB - PharmaCyte Biotech, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0358
0.0000 (0.00%)
At close: 3:47PM EDT
Stock chart is not supported by your current browser
Previous Close0.0358
Open0.0358
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0350 - 0.0367
52 Week Range0.0300 - 0.0700
Volume1,649,021
Avg. Volume2,005,563
Market Cap47.548M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-0.0030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product

    NEW YORK, NY, Oct. 16, 2019 -- PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and.

  • Business Wire

    PharmaCyte Biotech Successfully Completes Manufacturing of Clinical Trial Product

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova Singapore (Austrianova), has completed the first of two staggered and back to back manufacturing runs for the production of PharmaCyte’s clinical trial product. The first manufacturing run has been completed successfully.

  • Business Wire

    PharmaCyte Biotech Q&A Discussion with Cellular Biologist David A. Judd

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the latest in its series of Q&A articles that are conducted with some of the key team members of PharmaCyte’s research and development program related to its upcoming clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). This interview-style Q&A article is with David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has over 30 years of experience in the research and development of cell culture materials and methods for the culturing of various types of human cells.

  • Business Wire

    PharmaCyte Biotech Releases Shareholder Update Call Playback Information

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that an audio recording of the company’s shareholder update call, which was held on September 20, 2019, by PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, is now available for playback. Commenting on the shareholder call update, Mr. Waggoner said, “We would like to thank everyone who listened to our shareholder call update and, in particular, to those who submitted questions.

  • GlobeNewswire

    PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run

    During a conference call with shareholders late last week, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, told shareholders that the company is in the final days of the first of two back-to-back, staggered manufacturing runs, and that he is “very encouraged” by the reports he’s getting from Austrianova—the company conducting the manufacturing runs to produce the Cell-in-a-Box® capsules for PharmaCyte’s upcoming clinical trial. Once this first manufacturing run is completed successfully, the final stage in the process—testing those capsules and the live cells inside that make up the Cell-in-a-Box® technology—can begin.  The capsules will be placed into syringes and then those syringes will be frozen and stored in a freezer at Austrianova’s manufacturing facility in Thailand.  Soon thereafter, a representative sample of the Cell-in-a-Box® syringes will be thawed and a series of tests (release testing) will begin.  These FDA-required tests are necessary for PharmaCyte to be able to use its product in human beings in a clinical trial.

  • Business Wire

    PharmaCyte Biotech Provides Information on Upcoming Shareholder Update Call

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided the call information for PharmaCyte’s upcoming shareholder update call on September 20, 2019. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release. PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

  • Business Wire

    PharmaCyte Biotech Releases Results of Shareholder Meeting and Provides Information on Upcoming Shareholder Update Call

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of the Special Shareholder Meeting and provides information on the shareholder update conference call scheduled for next week.

  • Business Wire

    PharmaCyte Biotech Holding Special Shareholder Meeting Today

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced a reminder for shareholders that this morning a Special Shareholder Meeting will take place at the Courtyard Irvine Spectrum in Irvine, California, and will begin at 11:00 a.m. local time.

  • Business Wire

    PharmaCyte Biotech Releases New Video Documentary of Its Pancreatic Cancer Treatment

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has released a new video documentary of its pancreatic cancer therapy. The video, which was written and produced by Stock Market Media Group, uses storytelling to introduce the viewer to this hard-to-treat disease, the current options available for pancreatic cancer patients and then presents PharmaCyte’s leading product candidate – locally advanced pancreatic cancer (LAPC) - in full detail.

  • Business Wire

    PharmaCyte Biotech Releases New Interviews from Austrianova’s GMP Facility on Company’s Website

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, remains in Bangkok, Thailand, during the GMP-manufacturing process of its clinical trial material for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). Dr. Leonard Makowka, the Senior Strategic Advisor to the Chief Executive Officer and the Board of Directors, has now joined him in Bangkok, Thailand.

  • Business Wire

    PharmaCyte Biotech CEO in Thailand to Oversee Production of Final Clinical Trial Material for IND Submission

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, and his team are now in Bangkok, Thailand.

  • Business Wire

    PharmaCyte Biotech CEO Visiting GMP Facility with Cellular Biology Consultant During Production of Pancreatic Cancer Product

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, and PharmaCyte’s consultant cellular biologist, David Judd, will be on site at Austrianova’s GMP manufacturing facility in Bangkok, Thailand, as the production of its clinical trial material for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) is underway.

  • Business Wire

    PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has made further important progress in optimizing the complete manufacturing process, including significant improvement of the growth characteristics of the cells from PharmaCyte’s Master Cell Bank (MCB) after encapsulation.

  • Business Wire

    PharmaCyte Biotech Bioengineers Cell Line for Cannabis Program to Treat Cancers

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado, has bioengineered a human cell line designed to activate a cannabinoid prodrug in its quest to develop a Cell-in-a-Box®/cannabinoid therapy for serious forms of cancer, particularly brain cancer. Mark L. Rabe, MD, PharmaCyte’s Director of Cannabis Program Development, commenting on the bioengineered cell line said, “We now have a cell line into which the gene for a putative cannabinoid prodrug-activating enzyme has been ‘transfected’ or inserted into the cell’s DNA.

  • Business Wire

    PharmaCyte Biotech Advances Manufacturing Process for Clinical Trial in Pancreatic Cancer

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that advances have been completed in the manufacturing process for the clinical trial product that will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

  • GlobeNewswire

    PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA

    Clinical stage biotechnology company PharmaCyte Biotech (PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history.  Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for its development of a treatment for patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). PharmaCyte is a California-based biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®.  When the company recently announced that it had successfully encapsulated the live cells used in its therapy for patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC), and that those cells are now growing and dividing inside the Cell-in-a-Box® capsules, the news seemed to suggest that all of the pieces necessary to complete and submit the long overdue IND application to the FDA are falling into place for the company’s upcoming clinical trial in the treatment of LAPC.

  • GlobeNewswire

    World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer

    With PharmaCyte Biotech, Inc.’s (PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct its clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), and with the recent news that the live cells necessary for that clinical trial have been encapsulated and are growing, we decided to reach out to world-renowned clinician and oncologist, Dr. Manuel Hidalgo, to discuss his role as the Principal Investigator of PharmaCyte’s upcoming clinical trial, the company’s technology, the trial design and more. Dr. Hidalgo is a Professor of Medicine at the Harvard Medical School.  He is also the Chief of the Division of Hematology Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center (BIDMC).  Dr. Hidalgo is also Deputy Associate Director for Clinical Sciences at the Dana Farber Harvard Cancer Center.

  • Business Wire

    PharmaCyte Biotech Releases CEO Interview from The Big Biz Show

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has added a new CEO interview to the company’s website. Chief Executive Officer, Kenneth L. Waggoner, was featured on “The Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio program, on Friday, January 18th.

  • Business Wire

    PharmaCyte Biotech’s CEO Interviewing Live on The Big Biz Show

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its Chief Executive Officer, Kenneth L. Waggoner, will be featured in a live interview on “The Big Biz Show,” an Emmy Award-winning nationally syndicated radio and TV program, on Friday, January 18th.

  • Business Wire

    PharmaCyte Biotech Announces Encapsulation of Live Cells for Clinical Trial in Pancreatic Cancer

    PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced PharmaCyte’s partner, Austrianova, has successfully encapsulated the live cells used in PharmaCyte’s therapy for its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). The cells are now growing and dividing inside the Cell-in-a-Box® capsules.